BR0315194A - Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial - Google Patents

Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial

Info

Publication number
BR0315194A
BR0315194A BR0315194-8A BR0315194A BR0315194A BR 0315194 A BR0315194 A BR 0315194A BR 0315194 A BR0315194 A BR 0315194A BR 0315194 A BR0315194 A BR 0315194A
Authority
BR
Brazil
Prior art keywords
films
foams
drug release
therapeutic compositions
scrotal
Prior art date
Application number
BR0315194-8A
Other languages
English (en)
Inventor
Giovanni M Pauletti
Kishorkumar J Desai
Susan L Roweton
Donald C Harrison
Lynda M Sanders
Original Assignee
Umd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/444,634 external-priority patent/US7939098B2/en
Application filed by Umd Inc filed Critical Umd Inc
Publication of BR0315194A publication Critical patent/BR0315194A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

"COMPOSIçõES TERAPêUTICAS PARA LIBERAçãO DE DROGA PARA A, E ATRAVéS DA, COBERTURA EPITELIAL". Descrevem-se espumas de polímero e filmes para liberação de agentes terapêuticos para e através da mucosa oral, nasal ou vaginal, ou para e através do epitélio cornificado ou não-cornificado labial ou escrotal. Espumas de polímero ou filmes absorvíveis ou não-absorvíveis contendo um agente terapêutico incorporado onde o dito agente é liberado das ditas espumas ou filmes na colocação das ditas espumas ou filmes na superfície do epitélio oral, nasal, labial vaginal, ou escrotal. As espumas ou filmes têm uma taxa controlável de gelatinização, dilatação e degradação, e são formados em um dispositivo ou são aplicados como uma cobertura a uma superfície ou a um sistema mais complexo de liberação de droga.
BR0315194-8A 2002-10-31 2003-10-31 Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial BR0315194A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42326002P 2002-10-31 2002-10-31
US42492002P 2002-11-08 2002-11-08
US42565502P 2002-11-12 2002-11-12
US10/444,634 US7939098B2 (en) 2002-05-23 2003-05-22 Compositions and method for transmucosal drug delivery and cryoprotection
PCT/US2003/034643 WO2004041118A2 (en) 2002-10-31 2003-10-31 Therapeutic compositions for drug delivery to and through covering epithelia

Publications (1)

Publication Number Publication Date
BR0315194A true BR0315194A (pt) 2005-08-23

Family

ID=32314964

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315194-8A BR0315194A (pt) 2002-10-31 2003-10-31 Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial

Country Status (10)

Country Link
US (1) US20040151774A1 (pt)
EP (1) EP1556001A2 (pt)
JP (1) JP2006512409A (pt)
AU (1) AU2003286796A1 (pt)
BR (1) BR0315194A (pt)
CA (1) CA2504283A1 (pt)
MX (1) MXPA05004578A (pt)
NO (1) NO20051964L (pt)
NZ (1) NZ540318A (pt)
WO (1) WO2004041118A2 (pt)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DK2280020T3 (en) * 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20070249537A1 (en) * 2003-01-23 2007-10-25 Supernus Pharmaceuticals, Inc. Absorption enhancing agents
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP4524550B2 (ja) * 2003-08-19 2010-08-18 オイレス工業株式会社 摺動部材用樹脂組成物および摺動部材
AU2004273913A1 (en) * 2003-09-17 2005-03-31 Sharon M. Shaw Disinfectant, antibiotic and anesthetic containing device for injections and incisions
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
BRPI0414500A (pt) * 2003-09-19 2006-11-07 Drugtech Corp formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050113730A1 (en) * 2003-11-24 2005-05-26 Sca Hygiene Products Ab Absorbent Article Containing A Skin Care Product
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
JP4509118B2 (ja) * 2004-10-06 2010-07-21 エルメッド エーザイ株式会社 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006103657A2 (en) * 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
WO2006118210A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. ジヒドロピリジン系化合物の分解を防止する方法
JP4689340B2 (ja) * 2005-05-02 2011-05-25 キヤノン株式会社 吐出用液体医薬組成物
CN101170993A (zh) * 2005-05-09 2008-04-30 药物技术公司 修饰释放的药物组合物
DE102005033943A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US7658870B2 (en) * 2005-12-20 2010-02-09 University Of Hawaii Polymer matrix composites with nano-scale reinforcements
SE530184C2 (sv) 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
EP3546000A1 (en) * 2006-01-19 2019-10-02 Optinose AS Nasal administration
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
KR20170123724A (ko) * 2006-03-28 2017-11-08 자블린 파머슈티칼스 인코포레이티드 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
JP2009533471A (ja) * 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
CA2848648C (en) 2006-06-02 2017-10-10 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20070281008A1 (en) * 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
US20080015484A1 (en) * 2006-07-14 2008-01-17 Wolfensberger Joan A Apparatus and method for cleaning and disinfecting body piercings
ES2577390T3 (es) * 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
ATE464916T1 (de) * 2006-11-06 2010-05-15 Lohmann & Rauscher Gmbh & Co Kg Produkt zur versorgung von entzündungen, druckstellen und/oder aphten im oralbereich sowie verwendung eines solchen produkts
WO2008067573A2 (en) * 2006-12-01 2008-06-05 Tshwane University Of Technology Drug delivery system
US20080138383A1 (en) * 2006-12-07 2008-06-12 Jonathan David Bortz Compositions and methods for treating seizures
EP1964552B1 (en) * 2007-03-02 2009-08-26 Flamek Corp OÜ Analgesic composition of topically applied nonsteoridal antiinflammatory drugs and opioids
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
US20110159091A1 (en) * 2007-05-24 2011-06-30 Alan Stone Rapidly dispersible vaginal tablet that provides a bioadhesive gel
WO2009035387A1 (en) * 2007-09-14 2009-03-19 Softcure Pharmaceuticals Ab A medicament prepared using methotrexate and suitable for topical administration, for the treatment of a lower gastrointestinal tract inflammatory disease
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
DK2359807T3 (en) 2008-02-04 2017-10-16 Ferring Bv Monolithic vaginal rings comprising progesterone and methods of preparation and use thereof
WO2009108828A2 (en) * 2008-02-27 2009-09-03 Dr. Reddy's Laboratories Ltd. Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
WO2009141309A1 (en) * 2008-05-20 2009-11-26 N.V. Organon Delivery system for paliperidone
AR072114A1 (es) 2008-06-13 2010-08-04 Mannkind Corp Un inhalador de polvo seco y sistema para suministro de farmacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
CN101721404B (zh) * 2008-10-10 2014-08-13 北京人福军威医药技术开发有限公司 单硝酸异山梨酯鼻腔给药组合物及其制备方法
CN102143996A (zh) * 2008-10-30 2011-08-03 大卫·刘 微球形多孔可生物相容支架及制造该支架的方法和装置
CA2740509A1 (en) * 2008-10-30 2010-05-06 Medlite A/S Formulation for treatment of vaginal dryness
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US20100215730A1 (en) * 2009-02-20 2010-08-26 Intrepid Therapeutics, Inc. Compositions for Nasal Administration of Phenothiazines
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10350233B2 (en) * 2009-04-06 2019-07-16 Joshua D. Levine Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
US10039709B2 (en) * 2010-06-04 2018-08-07 Trilogic Pharma Llc Bioadhesive compositions for epithelial drug delivery
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
BR112013011942A2 (pt) * 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
WO2012070028A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical dosage form
CN102552888B (zh) * 2010-12-10 2015-02-11 上海高科联合生物技术研发有限公司 一种用于治疗哺乳动物子宫内膜炎的栓剂
WO2012127497A1 (en) * 2011-03-04 2012-09-27 Cadila Healthcare Limited Stable pharmaceutical compositions of ketorolac or salts thereof
US9987115B2 (en) * 2011-03-30 2018-06-05 Boston Scientific Scimed, Inc. Film encapsulated pelvic implant system and method
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013015599A2 (en) * 2011-07-28 2013-01-31 Yuhan Corporation Pharmaceutical composition for oral administration comprising bisphosphonic acid or its salt
CA2845634C (en) 2011-08-18 2021-07-13 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
PL2965759T3 (pl) 2012-02-06 2020-05-18 Innovative Med Concepts, LLC Terapia skojarzona związkiem przeciwwirusowym i inhibitorem cox-2 dla fibromialgii
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
FR3000080B1 (fr) * 2012-12-20 2015-01-30 Oreal Polycondensat de cyclodextrine insoluble dans l'eau ; utilisations comme agent de capture
AU2013361057A1 (en) * 2012-12-21 2015-07-30 Teva Pharmaceutical Industries Ltd. Oral transmucosal delivery of glatiramer acetate
EP2968080B1 (en) * 2013-03-12 2023-05-10 Synedgen, Inc. Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
JP6893086B2 (ja) 2013-03-13 2021-06-23 エーブリー デニソン コーポレイション 接着特性の向上
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
EP3082767A4 (en) 2013-12-17 2017-05-24 Zim Laboratories Limited Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CA3169840A1 (en) 2014-04-01 2015-10-08 TDL Innovations, LLC Methods and compositions for administering an active agent to the pleura of a patient
US10857100B2 (en) 2014-04-01 2020-12-08 Tdl Innovations Llc Methods and compositions for administering an active agent to the pleura of a patient
US20170224749A1 (en) * 2014-08-05 2017-08-10 Hprd - Health Products Research And Development Lda Vaginal composition for the treatment of urogenital infections
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR101492572B1 (ko) * 2015-01-14 2015-02-11 주식회사 대웅제약 신규 약학 조성물
WO2016137327A1 (en) 2015-02-27 2016-09-01 Polyganics Ip B.V. Drug eluting foams and the production thereof
WO2017077520A1 (en) 2015-11-06 2017-05-11 Ineb - Instituto Nacional De Engenharia Biomédica A composition for use in a method for prevention or treatment of human immunodeficiency virus infections
EP3173067B1 (en) * 2015-11-16 2018-11-14 Istanbul Universitesi Rektorlugu Mucoadhesive buccal in situ gel formulation
CN105542272B (zh) * 2015-12-20 2018-05-15 华南理工大学 一种专用于与聚乙烯醇薄膜复合的聚乙烯基础薄膜及其制备方法
EP3416628A1 (en) 2016-02-18 2018-12-26 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
US20180169012A1 (en) * 2016-12-16 2018-06-21 TDL Innovations, LLC Medical Foam for Delivery of an Active Agent
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) * 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
WO2019126744A1 (en) * 2017-12-21 2019-06-27 The Angiogenesis Foundation Compositions and methods for treating neoplasia
CN108498483B (zh) * 2018-05-08 2020-10-09 江南大学 一种pH/还原响应性聚氨基酸两性离子纳米颗粒的制备方法
CN109316444A (zh) * 2018-11-09 2019-02-12 南京道大药业有限公司 一种抗菌壳聚糖泡沫剂及其制备方法
US20240099984A1 (en) * 2019-10-15 2024-03-28 The University Of North Carolina At Chapel Hill A biodissolvable film for localized and efficient treatment of vulvodynia
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN111329846A (zh) * 2020-04-24 2020-06-26 云南伦扬科技有限公司 一种阴道杀菌贴膜及其制备方法
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel
WO2021260641A1 (en) * 2020-06-27 2021-12-30 Laurus Labs Limited Oral film of hiv drugs
CN114983927B (zh) * 2021-03-02 2024-03-29 复旦大学 一种温度敏感型即型凝胶系统及其制备方法和用途
WO2023022021A1 (ja) * 2021-08-17 2023-02-23 東亞合成株式会社 スポンジ及びその製造方法
CN115590826B (zh) * 2022-10-21 2023-12-19 北京安必奇生物科技有限公司 一种活性蛋白黏膜给药制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
US5458884A (en) * 1992-09-10 1995-10-17 Britton; Peter Bioerodible device for administering active ingredients
FI933979A0 (fi) * 1992-09-10 1993-09-10 Mcneil Ppc Inc Bioeroderbar anordning foer dosering av aktiva ingredienser
GB9414699D0 (en) * 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6905701B2 (en) * 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
JP2005522991A (ja) * 2001-11-16 2005-08-04 ジボダン エス エー 可食性フィルム
EP1539069A4 (en) * 2002-05-31 2007-11-14 Univ Mississippi TRANSMUCOSAL DELIVERY OF CANNABINOIDS

Also Published As

Publication number Publication date
WO2004041118A2 (en) 2004-05-21
NO20051964L (no) 2005-07-28
JP2006512409A (ja) 2006-04-13
EP1556001A2 (en) 2005-07-27
MXPA05004578A (es) 2005-07-26
CA2504283A1 (en) 2004-05-21
US20040151774A1 (en) 2004-08-05
NO20051964D0 (no) 2005-04-21
NZ540318A (en) 2007-09-28
WO2004041118A8 (en) 2005-06-09
AU2003286796A1 (en) 2004-06-07
WO2004041118A3 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
BR0315194A (pt) Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial
ES2237104T3 (es) Dispositivo portador de productos farmaceuticos adecuado para el aporte de compuestos farmaceuticos a superficies mucosas.
AU2020257142B2 (en) Biodegradable, active ingredient-eluting structural support
JP6568519B2 (ja) 医療用被覆器具
US20180344743A1 (en) Methods of treatment of anorectal and genital disorders
CO5130022A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
BRPI0411021A (pt) composição adesiva, método para a manufatura da mesma, artigo médico, e, dispositivo para administração farmacêutica
JP2005281322A (ja) 粘膜表面への、薬学的化合物の送達に適する薬学的キャリアデバイス
MXPA05008461A (es) Equipo para aplicar revestimiento de farmaco a un dispositivo medico en un cuarto del cirujano.
BRPI0411032A (pt) composição adesiva hidrófila, artigo médico, método para a fabricação da composição adesiva, e, dispositivo de administração transdérmica
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
DE69615583D1 (de) Örtliche arzneistoffabgabe in tieferen magendarmtraktabschnitten
JP7326516B2 (ja) 外用薬
ECSP993138A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.